Biohong Group’s Dermis-Targeted Supramolecular Self-Assembly (DTSS) Technology Global Launch Revolutionizes Chinese Skincare Technology

On December 6, 2023, Biohong Group organized the “DTSS Global Launch” event in Xi’an, China, unveiling five cutting-edge technology platforms with independent intellectual property rights. They introduced new raw materials, products, and an innovative CDMO platform based on these platforms, bringing highly efficient skincare technology to the industry. This advancement surpasses the limitations of traditional cosmetic ingredients and offers an all-in-one solution for the skincare industry. It signifies the progress of regenerative medicine technology and synthetic biology in skincare, contributing to the growth of domestic brands.

With a solid foundation of over 20 years in tissue engineering, regenerative medicine, and extensive research on skin and cells, Biohong Group has successfully translated several technological innovations into breakthroughs in regenerative skincare. Their Dermis-Targeted Supramolecular Self-Assembly Technology is composed of five major platforms: Polymicron™ Supramolecular Assembly Technology, Tai Bundle® Technology, Sticky Complex Tai® Supramolecular Assembly Technology, Polypearl™ Intelligent Assembly Technology, and Polysintai® Supramolecular Assembly Technology. These platforms effectively address issues such as poor transdermal penetration, permeability, stability, and irritation associated with existing skincare ingredients. They overcome the limitations of traditional skincare formulas and significantly enhance the effectiveness and quality of active ingredients.

Each technology platform generates innovative materials, including Tai Bundle® Blue Copper Peptide, Sticky Complex Tai® Licorice Compound, Polymicron™ Targeted Milk Exosomes, Polysintai® Supramolecular Assembly PDRN, Polypearl™ Retinol, and more. These materials drive the trend of regenerative skincare, offering diverse benefits such as anti-aging, repair, whitening, soothing, and hydration effects. They contribute to the development of the domestic skincare ingredient industry and establish a technological advantage for domestic brands.

During the launch event, Biohong Group introduced a regenerative science and technology innovation-oriented CDMO platform. This comprehensive platform provides CDMO services, including raw material manufacturing, product development, evaluation, production, and intellectual property layout, to global cosmetics companies, raw material suppliers, and cosmetics OEM companies. The group has already established partnerships with renowned domestic brands such as HFP and AFU, and their collaborative brands are gradually entering the market.

Leveraging their strong research capabilities in tissue engineering and regenerative medicine, the Biohong Group incorporates innovative materials from the five technology platforms into their skincare products under brands like Zhanmeiya, Fushengji, Shiguangshi, and Time Times. They continuously empower themselves and other domestic brands with regenerative skincare technology.

The development of core technologies and innovative materials is not only crucial for skincare companies to maintain their competitive edge but also a significant factor in their continuous growth. In the future, the Biohong Group will remain dedicated to regenerative medicine, utilizing the “Five Technology Platforms” as the foundation. They aim to provide more intelligent, targeted, and effective materials for the domestic skincare industry, consistently updating the integration and application of regenerative medicine in skincare, and driving the iteration and advancement of domestic skincare products. Their commitment is to become a globally influential, innovative regenerative science and technology research and development enterprise.

Media Contact
Company Name: Biohong Group
Contact Person: Yingchun Zhang
Email: Send Email
Country: China
Website: http://www.biohong.com/

HVAC Contractor Chicago Boosts Services for Furnaces, Water Heaters, Boilers, and Other Winter Needs

Browns Heating & Cooling provides top-notch heating and air conditioning services in Chicago and nearby areas. Since 2016, the company has offered transparent pricing and guaranteed customer satisfaction.

Browns Heating & Cooling and Ramod Brown are pleased to announce that the HVAC contractor Chicago company is ready to help customers prepare for the upcoming winter season. Of particular interest are furnaces, water heaters, and boilers necessary for comfort and convenience during the winter months. The EPA-certified technicians are trained in the latest technologies and can serve both residential and commercial customers. Trust the experts to service all makes and models, building a lasting relationship with clients. To better serve customers, the employees are EPA-certified and factory-trained. The technicians have the necessary skills and experience to complete any heating repairs correctly and efficiently.

The furnace repair Chicago company has been offering top-quality services since the locally owned-and-operated heating firm was launched in 2016. The technicians strive to meet individual customer needs, provide comprehensive services, charge affordable prices, and be upfront and honest. Before the technicians begin a repair, they give the customer a cost estimate to review. They take the time to explain any options that the customers have for moving forward with a job. These characteristics are part of what makes the company one of the top choices in the area for furnace and heating repair service firms.

Additional details are available at https://brownshvac.net/

Ramod Brown explained, “When you need an emergency furnace repair in Chicago and surrounding areas, there is no need to look beyond Browns Heating & Cooling. Our techs have the skills to complete heating repairs efficiently and adequately. Our job is to keep the heating system operating well, whether the Chicago furnace will not turn on at all or is making strange noises. Our technicians will arrive at your home as soon as possible with everything needed. They will be attired in the company uniform, treat the customer’s home with respect, and remove all waste when finished. At Browns Heating & Cooling, we can make any emergency furnace repair.

The technicians strive to fix issues such as no hot air, the heater not turning on, uneven heating, or strange smells or noises. When the techs are done with a repair, the heating system will run efficiently and reliably. Browns Heating & Cooling is dedicated to achieving the best possible customer satisfaction by providing continuous training and upholding the highest standards. Bryant has recognized the firm’s efforts, and the company is proud to be a Bryant Factory Authorized Dealer. This accolade acknowledges the commitment to quality and service. To ensure the best possible dependability and performance of equipment, only factory-authorized parts are utilized.

There can be many indications that the furnace needs to be repaired or replaced. The signs can range from strange noises and smells coming from the unit to pilot lights that won’t stay lit to the furnace not providing enough heat. The company offers 24/7 emergency services for furnace repair in Chicago. The company knows that when a repair is needed, it needs a response quickly. 

All of the technicians are fully licensed, insured, and bonded. They are proud of the quality of their work and strive for customer satisfaction with every job they do. The company offers furnace maintenance and tune-ups to ensure system efficiency. The technicians can diagnose and repair any issues that might be causing the furnace to malfunction.

About the Company: 

Browns Heating & Cooling has over a decade of service to Chicago area customers. The company offers emergency repairs and maintenance plans. A properly functioning furnace is a necessity when colder weather arrives.

Media Contact
Company Name: Browns Heating & Cooling
Contact Person: Ramod Brown
Email: Send Email
Phone: (708) 536-8134
Address:1 E Erie St
City: Chicago
State: IL 60611
Country: United States
Website: https://brownshvac.net/

Indianapolis Roof Replacement Company Handles Multiple Types Of Roofing Systems

Unlike other roofers, the Indianapolis roofing company can work with metal roofs. Metal Roofing Indianapolis specializes in them. Although the firm specializes in metal roofs, it also provides services for other types of roofs like asphalt shingles roofing, flat roofing, and cedar shake roofing.

Metal Roofing Indianapolis is pleased to announce the complete roofing solutions in Indianapolis for homeowners and business owners, from installations and replacements to coatings, restorations, and rejuvenation. The company also offers guttering, skylights, and attic venting services.

Business owners and homeowners in Indianapolis and surrounding areas who need roof replacement services are invited to set up a consultation with them. The company offers roof replacement and re-roofing services to both residential and commercial properties. The installers replace, restore, and coat roofs on commercial and residential properties in Indianapolis and the whole of Indiana.

The Indianapolis roof replacement company specializes in metal roofing. The company also works on other types of roofing, like flat roofs, asphalt shingles, composite, cedar shakes, and more. Indianapolis residential and commercial building owners can also take advantage of the professionals’ skills while working on gutters, skylights, and attic venting. Although the company specializes in metal roof systems, it has the expertise to install other types of roofing materials. The local roofing company provides both commercial and residential roofing services. The team of professionals strives to offer exceptional services; their values include loyalty, availability, and attention to detail.

The company provides homeowners with assistance for fixing or replacing their damaged roofs, choosing appropriate materials, inspecting them using methods like 17-point safety analysis or visual inspection, clearing debris from clogged gutters, or installing exterior siding replacements. Asphalt shingle roofing is one of the most commonly found forms of roofing in the United States. They are most commonly found  on homes and they are durable against weather elements yet cost-effective. They are attached to plywood rafters that form the roof deck. This form of roof installation must be performed promptly and efficiently by an experienced company.

Additional details about their roof replacement services are available at https://www.metalroofingindianapolis.net/roof-replacement/

Roofs serve an integral function in protecting commercial properties and tenants, employees, inventory, equipment, and other valuable assets. Commercial roofing installations should last decades before needing replacing; if the roofing system has reached its full age or is experiencing leakage issues, it may be time for a replacement. Keeping the commercial roof clear of debris, such as leaves or branches that fall, can prevent drains from clogging correctly and lead to structural issues on the roof. Regular inspection services by their experts can detect these problems before they cause significant issues.

The Indianapolis roofing contractors offer solutions tailored to the specific requirements of a commercial roof. Selecting appropriate materials, design specifications, and details are essential to its long-term performance, and the roof installation Indianapolis company offers a range of commercial roof styles, including TPO, EPDM, built-up roof, PVC, modified bitumen, spray polyurethane foam, metal roofing styles, as well as preventive maintenance plans, and roof coating services.

For home or business owners who are planning on installing a new roof, it is essential that they recognize its cost-intensive nature. Whether the professionals are installing a new roof or replacing one, roof replacement requires demolishing and disposing of the old system quickly, adding on additional expenses that add up quickly. 

The professionals conduct inspections to check for sagging, moisture issues, or missing shingles, as well as provide ice and water barriers to improve structural resilience and prevent leaks. Furthermore, the crew re-roofs homes, installs gutters, skylights, and paints both interiors and exteriors using quality energy-efficient materials, which the company sources responsibly from local providers while being licensed and insured and provides free estimates.

About the Company: 

Metal Roofing Indianapolis offers commercial and residential roofing systems in Indianapolis and throughout Indiana. Roof replacement is an undertaking that requires substantial money and time if the roof is damaged by inclement weather. The ideal contractor will provide experience and expertise.

Media Contact
Company Name: Metal Roofing Indianapolis
Contact Person: Irving Cannis
Email: Send Email
Phone: (463) 231-3049
Address:4826 W 34th St
City: Indianapolis
State: IN 46224
Country: United States
Website: https://www.metalroofingindianapolis.net/

Web Design Flagstaff: Local Agency the Top Choice for Outstanding Website Creation and SEO Solutions

Flagstaff-based JnM Web Creations excels in professional web design and SEO, offering unparalleled services focusing on long-term client partnerships and DIVI builder expertise.

JnM Web Creations is a dynamic web design Flagstaff outfit that has carved a niche in the industry with its excellent web design skills and first-rate client service. 

While JnM Web Creations provides services across various locations, its primary focus is Flagstaff website design and local SEO. Understanding the unique needs of local businesses, they tailor their services to enhance online visibility and engagement, specifically in the Flagstaff area. This localized approach sets them apart and demonstrates a keen understanding of the community they serve. 

Led by the husband and wife team of Josh and Megan Collier, the agency is passionate about creating unique websites that stand apart in an industry, imbuing their amiable personalities and passion for their work into the designs. The teamwork-based methodology guarantees that customers receive individualized attention, culminating in websites consistent with their brand identities. 

For more information, visit https://jnmwebcreations.com/

With a distinctive approach to website development, JnM Web Creations takes pride in working directly with customers to understand their specific requirements and preferences. Whether they are building a brand-new website from the ground up, updating an old one, or fixing technical problems, each project that JnM Web Creations works on benefits from its extensive knowledge and customer-focused approach.

With an exceptional track record of happy clients and an impressive portfolio of websites, JnM Web Creations differentiates itself from others with its commitment to pushing the envelope of innovative web design and delivering unmatched service to companies in Flagstaff and beyond—a commitment that stems from a sincere desire to see the long-term success of these companies. 

Web design represents JnM Web Creations’s core service offering. They are passionate about creating all kinds of websites for people at any stage of their business. By personalizing websites, they help clients tell a compelling story that resonates with current and future clients.

Designed to be visually appealing and customized to meet the client’s business needs, JnM Web Creations’ websites are mobile-friendly, SEO-friendly, user-friendly, and optimized for speed. 

Josh and Megan start the website design journey by brainstorming ideas with clients about the site they envision. Essentially, it’s a breaking-the-ice session that helps them understand what the client wants, from color schemes to budgets, while offering them tips on search engine optimization and related matters. Once the client accepts the terms of the proposal, the work begins. 

Using WordPress and the Divi Builder theme, the JnM Web Creations team will start working on creating the site in close communication with the client. The DIVI builder for WordPress is a reliable and adaptable tool that JnM Web Creations specializes in employing, enabling them to build attractive and practical websites precisely and efficiently to realize their clients’ visions.

JnM Web Creations are experts at fixing technical problems that arise during the web design process, quickly resolving issues to ensure the operation and integrity of their websites. 

Once the site is completed and published, training will be provided on managing the back end, from how to edit pages and update plugins to adding blogs and new pages. Divi is a user-friendly back-end program that is updated frequently, ensuring more tools in the future. 

JnM Web Creations offers flexible maintenance plans for businesses preferring to outsource. Alternatively, clients may opt for hourly service rates for editing and adding pages, upgrading plugins, and more.

As a fellow small business owner, JnM Web Creations understands the challenges that local Flagstaff businesses face. Josh and Megan have a passion for creating websites that meet the needs of their clients, ensuring mobile and SEO-friendly sites that help their clients get results.

About the Company:

Flagstaff-based agency JnM Web Creations specializes in customized web design and SEO services. Driven by the husband and wife team of Josh and Megan, the outfit’s expertise lies in the DIVI builder for WordPress, ensuring visually stunning and functional websites. Committed to long-term partnerships, the agency is focused on providing individualized services that offer local businesses mobile-friendly, SEO-friendly, and optimized for speed. JnM Web Creations also ensures continuous support on their websites.

Media Contact
Company Name: JnM Web Creations
Contact Person: Josh Collier
Email: Send Email
Phone: 928-458-0392
Address:7756 Moonbeam Drive
City: Flagstaff
State: AZ 86004
Country: United States
Website: https://jnmwebcreations.com

Sarcoidosis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Xentria, Inc., aTyr Pharma, Inc., Pfizer, United Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sarcoidosis pipeline constitutes 15+ key companies continuously working towards developing 15+ Sarcoidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Sarcoidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Sarcoidosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcoidosis Market.

 

Some of the key takeaways from the Sarcoidosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Sarcoidosis treatment therapies with a considerable amount of success over the years. 
  • Sarcoidosis companies working in the treatment market are Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others, are developing therapies for the Sarcoidosis treatment 
  • Emerging Sarcoidosis therapies in the different phases of clinical trials are- Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others are expected to have a significant impact on the Sarcoidosis market in the coming years.   
  • In September 2022, aTyr Pharma, Inc. revealed the initiation of dosing for the initial patient in the worldwide pivotal EFZO-FIT™ trial. This Phase III study aims to assess the effectiveness and safety of the company’s primary therapeutic candidate, efzofitimod, in comparison to a placebo among individuals diagnosed with pulmonary sarcoidosis, a significant type of interstitial lung disease (ILD).
  • In August 2022, The FDA has awarded Fast Track designation to efzofitimod (ATYR1923) for addressing pulmonary sarcoidosis. Additionally, efzofitimod has obtained FDA orphan drug designation specifically for the treatment of sarcoidosis.

 

Sarcoidosis Overview

The multisystem illness sarcoidosis, whose cause is uncertain, is typified by non-caseating granulomas in the organs. This disease primarily affects young individuals and is characterized by bilateral hilar lymphadenopathy and reticular opacities in the lungs.

 

Get a Free Sample PDF Report to know more about Sarcoidosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sarcoidosis-pipeline-insight

 

Emerging Sarcoidosis Drugs Under Different Phases of Clinical Development Include:

  • Abrocitinib: Pfizer
  • Inhaled Treprostinil: United Therapeutics
  • XTMAB-16: Xentria, Inc.
  • Efzofitimod: aTyr Pharma, Inc./Kyorin Pharmaceutical Co., Ltd
  • CMK389: Novartis
  • Namilumab: Kinevant Sciences GmbH
  • FP-020: Foresee Pharmaceuticals
  • LAM001: AI Therapeutics
  • OATD-01: Molecure

 

Sarcoidosis Route of Administration

Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Sarcoidosis Molecule Type

Sarcoidosis Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Sarcoidosis Pipeline Therapeutics Assessment

  • Sarcoidosis Assessment by Product Type
  • Sarcoidosis By Stage and Product Type
  • Sarcoidosis Assessment by Route of Administration
  • Sarcoidosis By Stage and Route of Administration
  • Sarcoidosis Assessment by Molecule Type
  • Sarcoidosis by Stage and Molecule Type

 

DelveInsight’s Sarcoidosis Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Sarcoidosis product details are provided in the report. Download the Sarcoidosis pipeline report to learn more about the emerging Sarcoidosis therapies

 

Some of the key companies in the Sarcoidosis Therapeutics Market include:

Key companies developing therapies for Sarcoidosis are – Xentria, Inc., aTyr Pharma, Inc., Pfizer, United Therapeutics, Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, and others.

 

Sarcoidosis Pipeline Analysis:

The Sarcoidosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
  • Sarcoidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Sarcoidosis drugs and therapies

 

Sarcoidosis Pipeline Market Drivers

  • Strategic alliances between the Pharmaceutical companies and universities, extensive research undertaking and funding are some of the important factors that are fueling the Sarcoidosis Market.

 

Sarcoidosis Pipeline Market Barriers

  • However, side-effects associated with the treatment of Sarcoidosis, lack of awareness among people in developing countries and other factors are creating obstacles in the Sarcoidosis Market growth.

 

Scope of Sarcoidosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Sarcoidosis Companies: Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others
  • Key Sarcoidosis Therapies: Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others
  • Sarcoidosis Therapeutic Assessment: Sarcoidosis current marketed and Sarcoidosis emerging therapies
  • Sarcoidosis Market Dynamics: Sarcoidosis market drivers and Sarcoidosis market barriers 

 

Request for Sample PDF Report for Sarcoidosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Sarcoidosis Report Introduction

2. Sarcoidosis Executive Summary

3. Sarcoidosis Overview

4. Sarcoidosis- Analytical Perspective In-depth Commercial Assessment

5. Sarcoidosis Pipeline Therapeutics

6. Sarcoidosis Late Stage Products (Phase II/III)

7. Sarcoidosis Mid Stage Products (Phase II)

8. Sarcoidosis Early Stage Products (Phase I)

9. Sarcoidosis Preclinical Stage Products

10. Sarcoidosis Therapeutics Assessment

11. Sarcoidosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sarcoidosis Key Companies

14. Sarcoidosis Key Products

15. Sarcoidosis Unmet Needs

16 . Sarcoidosis Market Drivers and Barriers

17. Sarcoidosis Future Perspectives and Conclusion

18. Sarcoidosis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sarcoidosis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Xentria, Inc., aTyr Pharma, Inc., Pfizer, United Therapeutics

COP28: Schneider Electric accelerates global supply chain clean power push

Energy management consultancy giant Schneider Electric has today announced the expansion of its Catalyze program, with tech giants Google, ASM, and HP signing up to the work with the group to help suppliers in their semiconductor supply chains access clean power.

The announcement, made on the sidelines of the COP28 Climate Summit in Dubai as part of ‘Energy Day’, followed news the company had also expanded its Energize program that provides a similar service to pharmaceutical companies.

Google, ASM, and HP join Intel and Applied Materials in the Catalyze program, with all the companies now working to encourage suppliers in their value chain to set climate goals and join buying cohorts for renewable power that should allow them to sign more competitive Power Purchase Agreements (PPAs) with renewables developers.

“We are delighted to welcome Google, ASM, and HP to the Catalyze program,” said Jean-Pascal Tricoire, chairman of Schneider Electric. “Their decision to join supports the ambition to accelerate the decarbonisation of supply chains. Scope 3 emissions have proven a challenge to track and manage, but the Catalyze program enables companies and their suppliers to engage and collaborate in their energy transition and decarbonisation.”

Michael Terrell, senior director of energy and climate at Google, said there was value in companies working together to tackle their supply chain emissions. “Transitioning to carbon-free semiconductor manufacturing is critical to reducing global emissions, and no company can do it alone,” he said. “We are excited to become a founding sponsor of the Catalyze program and look forward to working with our fellow sponsors and suppliers to expand the use of clean energy across this critical area of Google’s supply chain.”

The news came just a day after Schneider Electric confirmed its Energize program for the pharmaceutical industry now boasts 20 participating companies and has formed five PPA buyers cohorts since its original launch at the COP26 Climate Summit in Glasgow.

The companies calling on suppliers to take steps to curb their emissions, including new sponsors Boehringer Ingelheim, Charles River Laboratories, Roche, Merck KGaA and Haleon, and collectively represent $732.8bn in global annual revenue.

The five cohorts of suppliers – one in North America, one in the UK, and three in the EU – together represent an aggregate electricity demand in excess of 2 terawatt-hours (TWh) and are now seeking PPA deals to secure access to renewable power.

“Climate change and nature loss are creating new health threats, changing the spread and burden of disease and reinforcing health inequalities,” said Lisa Martin, chief procurement officer at GSK, a founding member of the Energize program. “This puts increasing pressure on healthcare systems, which already account for nearly five per cent of global emissions. Supply chain emissions are a shared challenge across our sector and we are collaborating to find shared solutions. By working with our peers to expand access to renewable energy across the sector’s supply chain, we can have a greater impact on decarbonizing health care systems and building climate resilience.”

Speaking to BusinessGreen on the sidelines of COP28, John Powers, vice president for global cleantech and renewables at Schneider Electric, said the programs were helping to both catalyse investment in clean energy capacity and drive down supply chain emissions that can account for over 70 per cent of the carbon footprint of many corporates.

He said the programmes were originally targeting countries where there is a mature PPA market and it makes good financial sense to switch to renewables, such as the US and EU. But he added that the company was also looking at other markets where PPAs were beginning to emerge, such as India, Brazil, and Australia, followed by Singapore, Japan, Malaysia, and Vietnam. The Catalyze program is also expected to have a big focus on markets in Asia where the semiconductor industry is concentrated.

Powers said the use of PPAs had the potential to cut costs and carbon for both corporates and their suppliers. “The pharma supply chain is chemicals, packaging, logistics,” he said. “Power is a big part of both their cost and their carbon.”

He added that the intention was to evolve the programs over time to look beyond orchestrating PPAs and also help suppliers set emissions targets and electrify their operations to tackle their direct emissions. “Let’s harvest the low hanging fruit then move up the tree,” he said.

However, he warned that efforts to boost supply chains’ use of renewables can face significant barriers in the form of policy environments that hamper the use of PPAs.

“In US states where corporates can sign PPAs around 70 per cent of new renewables projects are being driven by corporate demand,” he said. “In other regulated markets that is not happening. Our premise is we can go a lot faster and many corporate actors want to go faster than even the fastest governments. We will do it, if you just let us participate.”

As such, Schneider Electric is looking to bring together corporates, suppliers, developers, and local government to urge regulators to allow PPA pilot projects to demonstrate how collective purchasing of renewable power to help drive investment in new projects. He added that such investments were in line with the commitment to treble global renewables capacity, which over 100 countries have endorsed in Dubai and which is widely expected to make it into the final text of any agreement reached by governments.

Schneider Electric this week also formally joined the Energy Transition Accelerator, which has seen a coalition of companies come together to push for policies and projects that can help developing and emerging economies accelerate decarbonisation efforts.

Powers also signalled his backing for a series of proposed reforms to help drive down the cost of capital for clean energy projects in developing and emerging economies, warning that the main barriers to boosting renewables capacity remained permitting and grid connections, subsidies for fossil fuels, and the perceived long term investment risk in some markets.

“The private sector demand for renewables has never been higher and is growing fast, and it is moving beyond just the big corporates,” he said. “The more markets open up, the more we can allow that acceleration to occur.”

He added that the use of renewables in corporate supply chains is a trend that is building rapid momentum, and as such suppliers can expect more of their customers to call on them to embrace clean energy. “These schemes are the ‘carrot’,” he said. “Our partners then make decisions on a case-by-case basis on individual purchasing requirements. But some of our clients already have carbon metrics in deals that are real and significant.”

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: COP28: Schneider Electric accelerates global supply chain clean power push

Schneider Electric announces Google, ASM and HP have joined the Catalyze program for semiconductor supply chain decarbonization

Schneider Electric, the leader in the digital transformation of energy management and automation, today announced that Google, ASM and HP have joined the Catalyze program, which aims to accelerate access to renewable energy across the global semiconductor value chain and IT supply landscape, as new global sponsors.

The first-of-its-kind program was first announced in July, with sponsors Intel and Applied Materials. The announcement that three more leading technology companies have now joined as founding sponsors coincides with the COP28 United Nations Climate Change Conference taking place in Dubai.

Catalyze encourages suppliers from throughout the semiconductor industry ecosystem to collaborate to transition their value chain to renewable sources of energy. Participants are encouraged to make commitments to decarbonization and take collective action through the procurement of renewable energy, leveraging the purchasing power of buyer cohorts.

The energy transition within the value chain is imperative. According to a recent study by the SEMI Semiconductor Climate Consortium, the semiconductor industry’s carbon footprint was equivalent to 500Mt of CO2 in 2021—with 16% coming from the supply chain. By transitioning suppliers onto lower-carbon sources of energy and supporting them in other decarbonization actions like electrification, the industry can make a significant impact in its overall Scope 3 emissions.

“We are delighted to welcome Google, ASM, and HP to the Catalyze program. Their decision to join supports the ambition to accelerate the decarbonization of supply chains,” said Jean-Pascal Tricoire, Chairman, from Schneider Electric. “Scope 3 emissions have proven a challenge to track and manage, but the Catalyze program enables companies and their suppliers to engage and collaborate in their energy transition and decarbonization.”

“Transitioning to carbon-free semiconductor manufacturing is critical to reducing global emissions, and no company can do it alone,” said Michael Terrell, Senior Director of Energy and Climate, Google. “We are excited to become a founding sponsor of the Catalyze program and look forward to working with our fellow sponsors and suppliers to expand the use of clean energy across this critical area of Google’s supply chain”

“The planet needs urgent and decisive action to reduce the impacts of climate change. That’s why HP has committed to cut our end-to-end value chain emissions in half this decade, while still delivering innovative technology to our customers,” said Ernest Nicolas, Chief Supply Chain Officer, HP. “We’re proud to sponsor the Catalyze program to help drive industry progress toward decarbonization of the semiconductor and IT supply chain.”

“Collaboration is critical in reducing global emissions, no one company nor one industry alone can do it all. That is why Catalyze is so important, it enables companies to come together to make one plus one equal three,” said John Golightly, VP of Sustainability, ASM. “If we tried to do this alone with our suppliers it could never equal the impact and scale of the Catalyze program, and for that we are excited to be a founding sponsor.”

The Catalyze program strives to:

  • Combine energy purchasing power across the semiconductor value chain to accelerate the deployment of renewable energy projects
  • Provide suppliers – who may not have the capacity on their own – with the opportunity to participate in the market for utility-scale power purchase agreements (PPAs).
  • Enable any company that supplies to a Catalyze sponsor to join– across the IT supply landscape
  • Increase awareness of the availability of renewable energy in specific global regions where the semiconductor value chain is operational
  • Leverage numerous educational and digital technology platform engagements to drive measurable actions in supply chain decarbonization


About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric announces Google, ASM and HP have joined the Catalyze program for semiconductor supply chain decarbonization

Geographic Atrophy Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Annexon, Regenerative Patch Technologies, Apellis Pharma, Ionis Pharma, Astellas Pharma, Aviceda Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Geographic Atrophy pipeline constitutes 23+ key companies continuously working towards developing 25+ Geographic Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Geographic Atrophy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Geographic Atrophy Market.

 

The Geographic Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Geographic Atrophy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Geographic Atrophy treatment therapies with a considerable amount of success over the years. 
  • Geographic Atrophy companies working in the treatment market are Complement Therapeutics, Apellis Pharmaceuticals, Nanoscope Therapeutics, ONL Therapeutics, NGM Biopharmaceuticals, Annexon, Genentech, Belite Bio, Inc, Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., and others, are developing therapies for the Geographic Atrophy treatment 
  • Emerging Geographic Atrophy therapies in the different phases of clinical trials are- CTx001, APL-2006, MCO 020, ONL 1204, NGM621, ANX 007, OpRegen, Tinlarebant, AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, and others are expected to have a significant impact on the Geographic Atrophy market in the coming years.   
  • In February 2023, The US FDA has approved the New Drug Application (NDA) for Zimura intended for treating geographic atrophy, and has also given it priority review status. The Prescription Drug User Fee Act (PDUFA) goal date for Zimura is set for August 19, 2023.
  • In February 2022, NGM Biopharmaceuticals, Inc. revealed that the US Food and Drug Administration (FDA) has provided Fast Track designation to NGM621. NGM621 is a monoclonal antibody product designed to effectively block complement C3, aimed at treating individuals with geographic atrophy (GA) related to age-related macular degeneration.
  • In November 2022, NGM Biopharmaceuticals, Inc. revealed the unveiling of results from additional analyses conducted after the fact of its randomized, double-masked, sham-controlled CATALINA Phase II trial, which explored NGM621. NGM621 is a monoclonal antibody specifically developed to impede the activity of complement component 3 (C3) among patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These findings were presented at The Retina Society Annual Scientific Meeting.

 

Geographic Atrophy Overview

Geographic Atrophy (GA), alternatively termed atrophic age-related macular degeneration (AMD) or advanced Dry AMD, represents an advanced stage of age-related macular degeneration. It involves a gradual and permanent deterioration of the retina (involving photoreceptors, retinal pigment epithelium, choriocapillaris), resulting in a gradual decline in visual capabilities. GA is a persistent condition leading to progressive visual function impairment over time.

 

Get a Free Sample PDF Report to know more about Geographic Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/geographic-atrophy-ga-pipeline-insight

 

Emerging Geographic Atrophy Drugs Under Different Phases of Clinical Development Include:

  • CTx001: Complement Therapeutics
  • APL-2006: Apellis Pharmaceuticals
  • MCO 020: Nanoscope Therapeutics
  • ONL 1204: ONL Therapeutics
  • NGM621: NGM Biopharmaceuticals
  • ANX 007: Annexon
  • OpRegen: Genentech
  • Tinlarebant: Belite Bio, Inc
  • AVD-104: Aviceda Therapeutics
  • Zimura (avacincaptad pegol): Iveric Bio
  • ALK-001: Alkeus Pharmaceuticals
  • Risuteganib: Allegro Ophthalmics
  • Elamipretide: Stealth BioTherapeutics
  • PPY988: Novartis
  • VOY-101: Perceive Biotherapeutics, Inc.
  • OpRegen: Genentech, Inc.
  • NGM621: NGM Biopharmaceuticals, Inc
  • ANX007: Annexon, Inc.

 

Geographic Atrophy Route of Administration

Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.

 

Geographic Atrophy Molecule Type

Geographic Atrophy Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Geographic Atrophy Pipeline Therapeutics Assessment

  • Geographic Atrophy Assessment by Product Type
  • Geographic Atrophy By Stage and Product Type
  • Geographic Atrophy Assessment by Route of Administration
  • Geographic Atrophy By Stage and Route of Administration
  • Geographic Atrophy Assessment by Molecule Type
  • Geographic Atrophy by Stage and Molecule Type

 

DelveInsight’s Geographic Atrophy Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Geographic Atrophy product details are provided in the report. Download the Geographic Atrophy pipeline report to learn more about the emerging Geographic Atrophy therapies

 

Some of the key companies in the Geographic Atrophy Therapeutics Market include:

Key companies developing therapies for Geographic Atrophy are – Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Gyroscope Therapeutics Limited, and others.

 

Geographic Atrophy Pipeline Analysis:

The Geographic Atrophy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Geographic Atrophy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
  • Geographic Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Geographic Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Geographic Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Geographic Atrophy drugs and therapies

 

Geographic Atrophy Pipeline Market Drivers

  • Increase in Patient Burden, development of Novel Treatments are some of the important factors that are fueling the Geographic Atrophy Market.

 

Geographic Atrophy Pipeline Market Barriers

  • However, high Cost of Treatment, side-effects associated with the disease and other factors are creating obstacles in the Geographic Atrophy Market growth.

 

Scope of Geographic Atrophy Pipeline Drug Insight    

  • Coverage: Global
  • Key Geographic Atrophy Companies: Complement Therapeutics, Apellis Pharmaceuticals, Nanoscope Therapeutics, ONL Therapeutics, NGM Biopharmaceuticals, Annexon, Genentech, Belite Bio, Inc, Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., and others
  • Key Geographic Atrophy Therapies: CTx001, APL-2006, MCO 020, ONL 1204, NGM621, ANX 007, OpRegen, Tinlarebant, AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, and others
  • Geographic Atrophy Therapeutic Assessment: Geographic Atrophy current marketed and Geographic Atrophy emerging therapies
  • Geographic Atrophy Market Dynamics: Geographic Atrophy market drivers and Geographic Atrophy market barriers 

 

Request for Sample PDF Report for Geographic Atrophy Pipeline Assessment and clinical trials

 

Table of Contents

1. Geographic Atrophy Report Introduction

2. Geographic Atrophy Executive Summary

3. Geographic Atrophy Overview

4. Geographic Atrophy- Analytical Perspective In-depth Commercial Assessment

5. Geographic Atrophy Pipeline Therapeutics

6. Geographic Atrophy Late Stage Products (Phase II/III)

7. Geographic Atrophy Mid Stage Products (Phase II)

8. Geographic Atrophy Early Stage Products (Phase I)

9. Geographic Atrophy Preclinical Stage Products

10. Geographic Atrophy Therapeutics Assessment

11. Geographic Atrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Geographic Atrophy Key Companies

14. Geographic Atrophy Key Products

15. Geographic Atrophy Unmet Needs

16 . Geographic Atrophy Market Drivers and Barriers

17. Geographic Atrophy Future Perspectives and Conclusion

18. Geographic Atrophy Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Geographic Atrophy Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Annexon, Regenerative Patch Technologies, Apellis Pharma, Ionis Pharma, Astellas Pharma, Aviceda Therapeutics

Primary Biliary Cirrhosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Primary Biliary Cirrhosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Primary Biliary Cirrhosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Primary Biliary Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Primary Biliary Cirrhosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Biliary Cirrhosis Market.

 

Some of the key takeaways from the Primary Biliary Cirrhosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Primary Biliary Cirrhosis treatment therapies with a considerable amount of success over the years. 
  • Primary Biliary Cirrhosis companies working in the treatment market are Parvus Therapeutics, Selecta Biosciences, Hepagene Therapeutics, Ohara Pharmaceutical, Cour Pharmaceutical, Umecrine Cognition, Mirum Pharmaceuticals, Gannex Pharma, Dr Falk Pharma, Genfit, CymaBay Therapeutics, and others, are developing therapies for the Primary Biliary Cirrhosis treatment 
  • Emerging Primary Biliary Cirrhosis therapies in the different phases of clinical trials are- PVT-201, PDC-E2, HPG-1860, OP-724, CNP-104, Golexanolone, Volixibat, ASC42, Norucholic acid, Elafibranor, Seladelpar, and others are expected to have a significant impact on the Primary Biliary Cirrhosis market in the coming years.   
  • In January 2023, CymaBay Therapeutics, Inc. has disclosed a collaboration and licensing pact with Kaken Pharmaceutical Co., Ltd. This agreement pertains to the development and commercialization of CymaBay’s experimental drug seladelpar intended for treating primary biliary cholangitis in Japan. As per the terms, Kaken obtains an exclusive license to handle the development, marketing, and sales of seladelpar specifically for Primary Biliary Cirrhosis within Japan.
  • In August 2022, Gannex Pharma Co., Ltd., a subsidiary of Ascletis Pharma Inc., has completed the initial dosing phase in the United States for its drug-drug interaction (DDI) study of ASC42, a Farnesoid X Receptor agonist used in treating primary biliary cholangitis (PBC). Simultaneously, the DDI study conducted alongside an ongoing phase II clinical trial for PBC patients in China aims to gather additional data supporting forthcoming phase III trials scheduled in the United States, China, and the European Union.
  • In July 2022, CymaBay disclosed that the FDA has removed the clinical holds imposed on seladelpar for all three Investigational New Drug (IND) applications related to Nonalcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC), and Primary Sclerosing Cholangitis (PSC). Initially, in November 2019, the FDA had placed holds on all active INDs for seladelpar due to unusual histological findings noted in the Phase II NASH study, despite the absence of identified clinical or laboratory correlations.
  • GENFIT is presently assessing its in-house developed drug candidate, elafibranor, acting as a dual agonist for PPARα and PPARδ in Primary Biliary Cholangitis (PBC). The Phase III clinical trial ELATIVE (NCT04526665) is actively enrolling participants, aiming to validate the efficacy of elafibranor at 80mg by assessing alterations in biochemical parameters. Additionally, the trial seeks to explore its potential in alleviating pruritus while ensuring patient safety in PBC cases. Elafibranor secured Breakthrough Therapy designation from the FDA in April 2019 for treating PBC in adults with insufficient response to UDCA. Moreover, it received Orphan Drug Designation from both the FDA and the EMA (European Medicines Agency) in July 2019. In November 2022, GENFIT announced the anticipated release of Phase III data for elafibranor in primary biliary cholangitis (PBC) expected by the second quarter of 2023.
  • CNP-104 is a product in development that utilizes Cour’s nanoparticle platform (CNP), an innovative proprietary system. This technology merges disease-specific pathogenic antigens with advanced pharmaceutical nanoparticles designed to mimic the body’s natural elimination of deceased or dying cells. Cour’s platform has demonstrated its technological effectiveness in both clinical and preclinical settings. COUR is currently conducting a clinical study, with anticipated top-line data to be available in 2023. In January 2022, the US Food and Drug Administration (FDA) granted Fast Track designation to CNP-104 for addressing primary biliary cholangitis (PBC).

 

Primary Biliary Cirrhosis Overview

Primary biliary cirrhosis (PBC) is an autoimmune-related, chronic liver condition characterized by a gradual and persistent cholestatic disease. It involves damage to the bile ducts within the liver, potentially progressing to liver failure. Typically diagnosed in individuals between their fifth to seventh decades of life, this condition primarily affects women, constituting about 90% of cases.

 

Get a Free Sample PDF Report to know more about Primary Biliary Cirrhosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-pipeline-insight

 

Emerging Primary Biliary Cirrhosis Drugs Under Different Phases of Clinical Development Include:

  • PVT-201: Parvus Therapeutics
  • PDC-E2: Selecta Biosciences
  • HPG-1860: Hepagene Therapeutics
  • OP-724: Ohara Pharmaceutical
  • CNP-104: Cour Pharmaceutical
  • Golexanolone: Umecrine Cognition
  • Volixibat: Mirum Pharmaceuticals
  • ASC42: Gannex Pharma
  • Norucholic acid: Dr Falk Pharma
  • Elafibranor: Genfit
  • Seladelpar: CymaBay Therapeutics

 

Primary Biliary Cirrhosis Route of Administration

Primary Biliary Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Primary Biliary Cirrhosis Molecule Type

Primary Biliary Cirrhosis Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Primary Biliary Cirrhosis Pipeline Therapeutics Assessment

  • Primary Biliary Cirrhosis Assessment by Product Type
  • Primary Biliary Cirrhosis By Stage and Product Type
  • Primary Biliary Cirrhosis Assessment by Route of Administration
  • Primary Biliary Cirrhosis By Stage and Route of Administration
  • Primary Biliary Cirrhosis Assessment by Molecule Type
  • Primary Biliary Cirrhosis by Stage and Molecule Type

 

DelveInsight’s Primary Biliary Cirrhosis Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Primary Biliary Cirrhosis product details are provided in the report. Download the Primary Biliary Cirrhosis pipeline report to learn more about the emerging Primary Biliary Cirrhosis therapies

 

Some of the key companies in the Primary Biliary Cirrhosis Therapeutics Market include:

Key companies developing therapies for Primary Biliary Cirrhosis are – PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio, Gannex Pharma, Selecta Biosciences, Intercept Pharmaceuticals, Umecrine Cognition, Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals, HighTide Biopharma, Suzhou Zelgen Biopharmaceuticals, Merck Sharp & Dohme LLC, Kowa Pharmaceuticals, and others.

 

Primary Biliary Cirrhosis Pipeline Analysis:

The Primary Biliary Cirrhosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Biliary Cirrhosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Biliary Cirrhosis Treatment.
  • Primary Biliary Cirrhosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Primary Biliary Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Biliary Cirrhosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Primary Biliary Cirrhosis drugs and therapies

 

Primary Biliary Cirrhosis Pipeline Market Drivers

  • Increasing Cases of Primary Biliary Cirrhosis, increasing demand for effective treatment, increasing drug pipeline and FDA approval are some of the important factors that are fueling the Primary Biliary Cirrhosis Market.

 

Primary Biliary Cirrhosis Pipeline Market Barriers

  • However, high cost of the treatment, challenging clinical trial study, lacking consensus stratification protocol to identify patients for second line treatment and other factors are creating obstacles in the Primary Biliary Cirrhosis Market growth.

 

Scope of Primary Biliary Cirrhosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Primary Biliary Cirrhosis Companies: Parvus Therapeutics, Selecta Biosciences, Hepagene Therapeutics, Ohara Pharmaceutical, Cour Pharmaceutical, Umecrine Cognition, Mirum Pharmaceuticals, Gannex Pharma, Dr Falk Pharma, Genfit, CymaBay Therapeutics, and others
  • Key Primary Biliary Cirrhosis Therapies: PVT-201, PDC-E2, HPG-1860, OP-724, CNP-104, Golexanolone, Volixibat, ASC42, Norucholic acid, Elafibranor, Seladelpar, and others
  • Primary Biliary Cirrhosis Therapeutic Assessment: Primary Biliary Cirrhosis current marketed and Primary Biliary Cirrhosis emerging therapies
  • Primary Biliary Cirrhosis Market Dynamics: Primary Biliary Cirrhosis market drivers and Primary Biliary Cirrhosis market barriers 

 

Request for Sample PDF Report for Primary Biliary Cirrhosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Primary Biliary Cirrhosis Report Introduction

2. Primary Biliary Cirrhosis Executive Summary

3. Primary Biliary Cirrhosis Overview

4. Primary Biliary Cirrhosis- Analytical Perspective In-depth Commercial Assessment

5. Primary Biliary Cirrhosis Pipeline Therapeutics

6. Primary Biliary Cirrhosis Late Stage Products (Phase II/III)

7. Primary Biliary Cirrhosis Mid Stage Products (Phase II)

8. Primary Biliary Cirrhosis Early Stage Products (Phase I)

9. Primary Biliary Cirrhosis Preclinical Stage Products

10. Primary Biliary Cirrhosis Therapeutics Assessment

11. Primary Biliary Cirrhosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Biliary Cirrhosis Key Companies

14. Primary Biliary Cirrhosis Key Products

15. Primary Biliary Cirrhosis Unmet Needs

16 . Primary Biliary Cirrhosis Market Drivers and Barriers

17. Primary Biliary Cirrhosis Future Perspectives and Conclusion

18. Primary Biliary Cirrhosis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Biliary Cirrhosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio

A Trailblazing Force in Soulful Christian Music – James Emerich Inspires with a Heartfelt New Record ‘God?!’

A Trailblazing Force in Soulful Christian Music - James Emerich Inspires with a Heartfelt New Record ‘God?!’
With stirring tunes and relatable lyricism, James Emerich’s rhythmic musical compositions set him apart as a true visionary

Embarking on a new chapter, James Emerich presents his latest musical venture — ‘God!?’ a 12-track album rooted in Christian themes inspired by his life experiences. Scheduled for release on December 6, 2023, this offering promises to be a soul-stirring collection that reflects Emerich’s spiritual journey and creative prowess.

At the core of James Emerich’s musical endeavors lies a multifaceted artist who defies convention. His upcoming album, slated for release on December 6, 2023, stands as a testament to Emerich’s commitment to spiritual exploration through music.

As a singer-songwriter, Emerich navigates the realms of intuition and eclecticism, infusing his compositions with a universal appeal that transcends borders. One distinctive facet of Emerich’s artistry is his involvement in every facet of his musical projects.

From the inception of an idea to the final notes resonating in his compositions, Emerich’s creative influence is omnipresent. He not only writes the music and lyrics but also intricately designs the arrangements that breathe life into each track.

To complement his sonic tales, Emerich assumes the role of a visual storyteller, crafting videos that add a layer of depth to his narratives. What sets Emerich apart, however, is not just his technical proficiency but the soulful impact his music leaves on listeners.

Reviews attest that his compositions possess the remarkable ability to touch the depths of people’s souls, fostering a profound connection between artist and audience.

A unique and fascinating aspect of Emerich’s creative process is the ethereal source of his melodies. His songs manifest in his dreams, where he intuitively hears the melodies as he sleeps—a testament to the deep well of inspiration from which Emerich draws.

In essence, James Emerich is not just a singer-songwriter; he is a storyteller, a visionary weaving tales of faith, life, and spirituality through the universal language of music. His new Christian-inspired album, with tracks such as “Oh God,” “Missing Mama” and “Till Death Do Us Part” weave a mesmerizing and spellbinding image of what matters in the world. Emerich’s music beckons, inviting audiences to partake in an enriching odyssey of sound and soul.

Visit James Emerich’s official website to explore the richness of his musical universe! Follow the artist’s musical journey on Spotify and YouTube to experience the magic of his multi-genre prowess.

Through his music, Emerich extends an invitation to listeners to embark on a spiritual and artistic journey—one where authenticity, intuition, and creativity converge!

ABOUT

James Emerich emerges as a formidable force in the realm of Christian music, transcending conventional boundaries as an intuitive, eclectic, and international recording artist. With profound skills as a singer, pianist, and songwriter, Emerich crafts musical narratives that resonate globally.

The artist’s unique approach extends beyond vocals and instrumentation; he pens every lyric, designs arrangements, and personally creates captivating videos to breathe life into his artistic journey.

LINKS

Facebook: https://www.facebook.com/james.emerich.5

Twitter: https://twitter.com/emerich_james

YouTube: https://www.youtube.com/channel/UCfVQNqepToYsV8BUZnS8Oyw

Spotify: https://open.spotify.com/artist/1KhWkNAiBwUntBFCJ9UCev

SoundCloud: https://soundcloud.com/james-emerich

Reverbnation: https://www.reverbnation.com/jamesemerich?profile_view_source=header_icon_nav

LinkedIn: https://www.linkedin.com/in/jemerich/

Media Contact
Company Name: James Emerich
Email: Send Email
Phone: 3863663119
Address:111 Maple ave
City: Windsor
State: CT
Country: United States
Website: https://www.facebook.com/james.emerich.5